FDA warning letters
A warning letter is FDA's formal notice that a company broke the law, usually found during an inspection. The company has 15 working days to reply. Letters that go unanswered lead to seizures, import bans or court orders.
99 letters match. Newest first.
-
DrugsWoodbine Products Company Inc.
Inspection found Woodbine Products, an Ohio OTC drug maker, failed to test incoming ingredients like glycerin and propylene glycol for identity.
High risk -
DrugsSpa De Soleil, Inc.
FDA cites Spa De Soleil for CGMP violations in OTC topical drugs, including water system failures and missing component identity testing.
High risk -
DrugsSklar Personal Care Inc.
Sklar Personal Care’s drug facility failed CGMP (current good manufacturing practice), including untested raw materials and inadequate cleaning, process validation, and quality oversight.
High risk -
DrugsCDL Services, Inc. DBA Technichem
FDA warned CDL Services (Technichem), an Anaheim OTC drug maker, that it released hand sanitizer and hand soap batches without testing.
High risk -
DrugsDeVere Manufacturing Inc.
FDA warned DeVere Manufacturing in Janesville, Wisconsin, that its OTC hand sanitizers are adulterated after a June 2025 inspection found CGMP failures.
High risk -
DrugsWorld Perfumes Inc.
World Perfumes failed to test drug ingredients for toxic contaminants and had inadequate water, FDA says.
High risk -
DrugsDermaRite Industries, LLC
DermaRite failed CGMP and sold unapproved, misbranded OTC topical drugs, FDA says.
High risk -
DrugsRNA Bio/Pharma, Incorporated
FDA found RNA Bio/Pharma failed to test homeopathic oral liquid drugs for dangerous contaminants and did not validate its water system.
High risk -
DrugsNaturich Cosmetique Labs
FDA warned Naturich Cosmetique Labs over inadequate manufacturing controls for over-the-counter topical drugs, including contaminated water and untested ingredients.
High risk -
DrugsKabana Skin Care LLC
Kabana Skin Care failed to test OTC drug ingredients and finished products, prompting a recall and halt of U.S. drug manufacturing.
High risk -
DrugsMedical Chemical Corporation
FDA warned Medical Chemical Corp over manufacturing violations, unapproved Tincture Green Soap, and improper drug listing.
High risk -
DrugsNature’s Fusions LLC
FDA cited Nature's Fusions for over-the-counter hand sanitizer manufacturing with inadequate stability, component and finished-product testing, and water controls.
High risk -
DrugsNingbo Riway Industrial Co., Ltd.
Ningbo Riway Industrial, an OTC drug maker in China, was cited for manufacturing-practice failures and unapproved antiseptic wipes.
High risk -
DrugsDyno Manufacturing, Inc.
Dyno Manufacturing’s OTC hand sanitizer and antibacterial soap drugs lacked raw-material identity testing and other required manufacturing controls.
High risk -
DrugsRite-Kem Incorporated
FDA warned Rite-Kem over inadequate current good manufacturing practice testing of over-the-counter drugs, including hand sanitizers and antimicrobial products.
High risk -
DrugsLinghai ZhanWang Biotechnology Co., Ltd
Linghai ZhanWang Biotechnology's OTC drugs, including antimicrobial wipes, fail manufacturing quality rules; FDA cites missing tests.
High risk -
DrugsShantou Kangjie Daily Chemical Industry Co., Ltd
FDA warns Shantou Kangjie over CGMP failures for OTC drugs, including untested ethanol and no quality unit.
High risk -
DrugsImperial Palace Commodity -Dongguan- Co., Ltd.
FDA warns Chinese maker of OTC alcohol wipes that weak component testing and process validation make its drugs adulterated.
High risk -
DrugsKardesler Ucan Yaglar Sanayi Anonim Sirketi
Turkey-based OTC drug maker Kardesler Ucan failed to test glycerin, propylene glycol and ethanol for dangerous impurities and is on US import alert.
High risk -
DrugsSombra Cosmetics, Inc.
FDA warned Sombra Cosmetics of OTC drug CGMP violations, including inadequate water controls and component testing.
High risk -
DrugsHangzhou Huiji Biotechnology Co., Ltd.
FDA warned Hangzhou Huiji Biotechnology over CGMP failures in OTC hand sanitizers, including missing glycerin and ethanol safety tests.
High risk -
DrugsZhejiang Qimei Cosmetics Co., Ltd.
Zhejiang Qimei Cosmetics drew an FDA warning for CGMP violations in sterile-labeled OTC isopropyl alcohol prep pads.
High risk -
DrugsLittle Moon Essentials, LLC
FDA warns Little Moon Essentials over CGMP failures and unapproved topical analgesic drugs made in Dania Beach, Florida.
High risk -
DrugsDiamond Chemical Co., Inc.
Diamond Chemical Co. in East Rutherford, NJ, made OTC hand sanitizers without required ingredient and finished-product testing or process validation.
High risk -
DrugsEnviroServe Chemicals & Cleaners Ltd.
EnviroServe's SOPURE hand sanitizer had manufacturing-quality violations and was sold as an unapproved, misleadingly labeled drug.
High risk -
DrugsAnuMed International, LLC
FDA warned AnuMed International about unapproved drugs, misleading FDA claims, and manufacturing quality failures.
High risk -
DrugsNowrez & Ismail Shukri Company
FDA warns Jordanian OTC drug maker Nowrez & Ismail Shukri over CGMP violations and import alert.
High risk -
DrugsYahon Enterprise Co., Ltd.
FDA warned Yahon Enterprise over manufacturing quality failures for OTC antiseptic wipes after a December 2023 inspection.
High risk -
DrugsLandy International
FDA found Landy International’s OTC hand sanitizers adulterated after a 2023 inspection revealed missing testing, unsafe water, and data integrity failures.
High risk -
DrugsTCT Nutraceuticals SDN. BHD
FDA warns TCT Nutraceuticals over manufacturing-rule failures in OTC hand sanitizer, including no methanol testing.
High risk -
DrugsAruba Aloe Balm N.V.
Aruba Aloe Balm N.V. made OTC drugs with methanol-contaminated ethanol and failed CGMP, prompting recall and import alert.
High risk -
DrugsSeatex, LLC
FDA: Seatex made hand sanitizer on equipment also used for floor cleaner and skipped ingredient identity tests.
High risk -
DrugsNatuzen Co., Ltd.
Natuzen Co., Ltd. failed drug manufacturing rules for OTC products including Atoren Hand Sanitizer, with no methanol testing, cleaning validation, or quality unit.
High risk -
DrugsSeatex, LLC
Seatex, LLC made OTC hand sanitizer drugs with inadequate current good manufacturing practice (CGMP), including shared equipment with industrial chemicals and missing component testing.
High risk -
DrugsGlobal Cosmetics Company Limited
FDA warns Global Cosmetics over manufacturing quality failures in OTC hand sanitizer, including no methanol testing of ethanol.
High risk -
DrugsMaster Paints & Chemicals Corp.
FDA warned Master Paints & Chemicals Corp. over inadequate testing and quality oversight for OTC drugs including hand sanitizer.
High risk -
DrugsBodywell Natural Skin Care Inc.
FDA warned Bodywell Natural Skin Care that its OTC hand sanitizer and Dermalere creams were adulterated due to CGMP failures and unapproved drug claims.
High risk -
DrugsDeqing Jiarou Daily Chemical Co., Ltd.
Deqing Jiarou failed current good manufacturing practice (CGMP) for OTC hand sanitizer, including no methanol testing of ethanol.
High risk -
DrugsHigley Industries, Inc.
FDA warns Higley Industries over CGMP failures in OTC drug manufacturing, including untested ethanol and glycerin.
High risk -
DrugsCosmetic Specialty Labs, Inc.
FDA warned Cosmetic Specialty Labs after an inspection found manufacturing failures in OTC drugs and an unlisted product.
High risk -
DrugsNantong Furuida Packaging Products Co., Ltd.
Nantong Furuida, an over-the-counter drug manufacturer, failed required manufacturing controls and methanol checks, leading to an FDA import alert.
High risk -
DrugsPrime Lab LLC
Prime Lab LLC failed U.S. drug manufacturing quality rules for over-the-counter hand soaps and sanitizers, including raw-material testing and shared toxic equipment.
High risk -
DrugsInopak, Ltd.
Inopak, Ltd. was warned of CGMP (current good manufacturing practice) violations after inspection: poor quality oversight of contract-made hand sanitizer and missing stability testing.
High risk -
DrugsXiamen Wally Bath Manufacture Co., Ltd.
FDA warns Xiamen Wally Bath over current good manufacturing practice failures for over-the-counter hand sanitizer, including raw material and release testing gaps.
High risk -
DrugsSaruhan Kimya Ve Temizlik Urunleri Sanayi Ticaret Anonim Sirketi Corlu Subesi
FDA found manufacturing violations at Turkish OTC drug maker, including missing identity, release, and stability testing for hand sanitizers.
High risk -
DrugsFuller Industries Inc.
FDA warns Fuller Industries over current good manufacturing practice violations in OTC hand soaps and sanitizers, including quality oversight and ingredient testing.
High risk -
DrugsPharmaplast S.A.E.
FDA cited Pharmaplast S.A.E. for failing to test drug components, including glycerin and ethanol, for dangerous contaminants.
High risk -
DrugsChemical Services Group, Inc./Royal Chemical Company
Royal Chemical Company made OTC hand sanitizer on equipment shared with industrial chemicals, and FDA found cleaning, supplier testing and quality unit failures.
High risk -
DrugsOmega Packaging Corp
Omega Packaging Corp failed to test hand sanitizer ingredients and validate processes, FDA found.
High risk -
DrugsNuGeneration Technologies LLC
FDA inspected NuGeneration Technologies' Emeryville, California drug plant and found CGMP failures in hand sanitizer release testing, ingredient and water testing, stability and process validation.
High risk